SlideShare a Scribd company logo
1 of 40
Download to read offline
PRESENTER: DR AJAY
MODERATOR: DR SAKET KUMAR
SGE KGMU,
Current Evidence of D1 - D2
Gastrectomy
OUTLINE
 INTRODUCTION
 NODAL STATIONS
 DEFINITIONS
 CURRENT EVIDENCE
1. D1 GASTRECTOMY
2. D2 GASTRECTOMY
 CONCLUSION
INTRODUCTION
 Gastric cancer is the second leading worldwide cause of cancer death
and the fourth most common cancer .
 The high mortality rate - advanced disease at presentation and
relatively aggressive biology.
 Early lesions - asymptomatic and infrequently detected
 Prognosis has improved, attributable to advances in surgical treatment,
postoperative care, and multimodality therapy.
 In all cases surgery is the standard of care for all resectable tumours:
radical gastrectomy with regional lymphadenectomy
(Surgical treatment of gastric cancer: 15-year follow-up results of the randomised
nationwide Dutch D1D2 trial.Songun I et al Lancet Oncol. 2010 May; 11(5):439-49)
 Nodal involvement - most important prognostic factor.
Hence the importance to lymphadenectomy and its extension.
SURGICAL ANATOMY
TIMELINE OF EARLY TRENDS
1950s
 Failure of limited surgery to control disease loco-regionally by Gordon
McNeer.
 >20% cancer recurrence in the non-resected perigastric nodes or the
gastric bed
1960s
 the Japanese Society suggested removal of the appropriate number of
tiers would increase the chance of negative “lymphadenectomy
margins”
INTRODUCTION
 The lymph node stations - precisely defined by the Japanese Gastric
Cancer Association (JGCA),
formerly known as the Japanese Research Society for Gastric Cancer
 Aim of Japanese classification  a common language for the clinico-
pathological description of gastric cancer.
 Previously the JGCA divided these stations into four levels (N1 through
N4)
D2 distal gastrectomy
DEFINITIONS OF DIFFERENT LEVELS OF LYMPH NODE
DISSECTION
 For total gastrectomy
1. D1 lymphadenectomy are stations from No.1 to 7;
2. D1+ includes D1 stations plus stations No.8a, 9, and 11p, and
3. D2 includes D1 stations plus stations No.8a, 9, 10, 11p, 11d, and 12a.
For tumors invading the esophagus,
1. D1+ includes N0. 110 and
2. D2 includes Nos. 19,20,110 and 111.
 For distal gastrectomy,
1. D1 lymphadenectomy includes stations No.1, 3, 4sb, 4d, 5, 6 and 7;
2. D1+ includes D1 stations plus stations No.8a, and 9, and
3. D2 includes D1 stations plus stations No.8a, 9, 11p, and 12a.
D1 Gastrectomy
 Early forms not suitable for endoscopic treatment -> a D1 or D1 plus
lymphadenectomy in cases with clinically negative nodes.
(Japanese gastric cancer treatment guidelines 2010 (ver. 3) 2011 Jun; 14(2):113-23)
D1 lymphadenectomy along with
1. proximal gastrectomy and
2. pylorus preserving gastrectomy
only recommended for T1N0 disease.
 When lymph nodes are clinically positive, a D2 dissection
1. removal of stations 12a and 11p in subtotal gastrectomy, and
2. stations 12a, 11d and 10 in total gastrectomy
D2 Gastrectomy
 Systematic (D2) Lymphadenectomy
 Resection of the perigastric lymph nodes and those along the feeding
vessels (N2) with the gastrectomy specimen.
 will vary according to the position of the primary tumour
D2 Gastrectomy
Indication
 Curative Treatment for Resectable cancer of stomach
(Results are best in patients with stage II and IIIa disease)
Contraindication
 Stage IV disease
D2 Lymphadenectomy –
An ACCEPTED STANDARD procedure
for gastric cancer
Why ?
CURRENT EVIDENCE
Rationale for D2 resections
 LN metastasis – a significant prognostic factor
 Occult metastasis in N2 nodes of JRSGC in EGC(2-17%)
 Decreased incidence of recurrence in gastric bed & perigastric
lymphatics
 Appropriate staging & standardisation of results
 Absence of a truly effective adjuvant therapy
Japanese and Korean experience
5yr survival rates by Pathologic stage
Stage 1st period
1963-66
2ndperiod
1969-73
3rdperiod
1974-78
4th period
1979-90
I 94.4% 96.4% 96.6% 100%
II 56.1% 71.8% 72% 81.2%
III 30.1% 43.8% 44.8% 61%
IV 9.3% 13.1% 7.7% 14%
• D2 - accepted in Far East as the standard treatment for both
(EGC) and (AGC) for many decades.(mostly based on observational
and retrospective studies)
5yr survival rates by LN dissection
Stage 1st period
1963-66
2ndperiod
1969-73
3rdperiod
1974-78
4th period
1979-90
D0 26% 20.5% 18.4% 32.5%
D1 42.4% 46% 49.8% 62.1%
D2/D3 48.1% 61.6% 64.2% 76.9%
Japanese experience
Western experience
 Surgeons from the West have conventionally preferred the D1 approach
because of
(a) lower incidence of gastric cancer and therefore scant opportunities
(b) lack of training in performing D2 resection compared with their
Japanese counterpart
(c) technical demands with unproven benefits based on a number of RCTs
(d) fear of increased risk of complications and even deaths
Initial Western experience
Results of prospective randomized trials
Name Study
period
No of pts Post op
morbid
Post
opMort
5yr
survival
South
Africa
(Dent et al)
1982-
1986
D1 D2 D1 D2 D1 D2 D1 D2
22 21 15 30 0 0 0.69 0.67
Dutch
Gastric
cancer trial
1983-
1993
380 331 25 43 4 10 42 47
MRC
trial,UK
1986-
1993
200 200 28 46 6.5 13 35 33
•MRC, Dutch and Italian RCTs - conducted to show a survival benefit of
D2 over D1.
•Both the MRC and the Dutch trials failed to show a survival benefit
 Only 15 years after the conclusion of accrual, Dutch trial reported
significant decrease of recurrence after D2 procedure.
 Italian RCT could demonstrate a benefit for patients treated with D2
gastrectomy without splenopancreatectomy.
 It has been suggested in several national guidelines including NCCN as
the recommended procedure for patients with AGC.
THE RCTs
South African Trial
 Dent et al in South Africa randomized 43patients.
 Major findings were that blood transfusion requirements, operating
time and hospital stay were longer with extended lymphadenectomy.
 At a median follow-up of 3.1 years no benefit regarding survival was
seen.
Hong Kong Trial
 Robetson et al randomized 55 patients in Hong Kong
 Operating time, transfusion requirements and hospital stay, all
increased with extended lymphadenectomy.
 Contrary to the expectations overall survival was significantly worse
and this was attributed to the impact of increased blood transfusion.
UK MRC Trial
 In hospital mortality was high in both groups compared to high volume
Asian centers, and significantly higher in the D2 versus D1 arm (13 vs.
6.5%)
 No significant difference in overall survival at 5 years (D1 35%; D2
33%; P = 0.43).
 Cons
The authors found - additional mortality in the D2 group could be
attributed to the performance of distal pancreatectomy and
splenectomy
Dutch Trial
 Patients in the D2 group had
1. significantly higher rates of complications (43 vs. 25%; P < 0.001)
2. post-operative death (10 vs. 4% P = 0.004).
 Overall survival at 5 years was not statistically different (45% for D1;
47% for D2).
 15 year-follow up of the Dutch study
[Surgical treatment of gastric cancer: 15-year follow-up results of the randomised
nationwide Dutch D1D2 trial. Songun et al Lancet Oncol. 2010 May; 11(5):439-49]
1. Loco-regional recurrence rate is significantly lower in patients
treated with D2 lymphadenectomy vs D1.
2. Survival benefit with the enlarged dissection.
 Studies recently demonstrated that even in Europe trained surgeons
could safely perform D2 with spleen and pancreas preservation and
 More favourable recurrence pattern and cancer-related survival,
 D2 seemed to be the recommended treatment for patients
with resectable gastric cancer .
[Extended lymph node dissection without routine spleno-pancreatectomy for treatment
of gastric cancer: low morbidity and mortality rates in a single center series of 250
patients.Biffi R et al J Surg Oncol. 2006 Apr 1; 93(5):394-400]
 Limitations
-- outcome of multivariate analysis was not reported
-- protocol deviations
1. noncompliance (ie, performance of less dissection than specified)
2. contamination (ie, performance of more extensive dissection than
specified)
Italian Trial
 Italian Research Group for Gastric Cancer (GIRCG) database
1. Proximal tumors and diffuse-mixed type show a relative increase
2. Endoscopic resections, are much less adopted in the West.
3. The GIRCG guidelines advice a D2 lymphadenectomy in clinically
early forms not suitable for endoscopic treatment
(The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer.De Manzoni G et al
Updates Surg. 2014 Mar; 66(1):1-6.)
 D2 dissection - limited risk of complications and mortality in the West, when
performed in specialized centers and avoiding spleno-pancreatectomy
[RCT comparing survival after D1 or D2 gastrectomy for gastric cancer.Degiuli M et al
Italian Gastric Cancer Study Group. Br J Surg. 2014 Jan; 101(2):23-31].
 Only in selected cases more limited procedures (D1 plus) are adviced by
the GIRCG group.
1. high-risk patients (age > 70 yrs)
2. early forms with favourable pathological characteristics.
 Limitations
1. Poor accrual
2. Closed after 8 years with a low statistical power as only 267 patients
were randomized.
Taiwanese Trial
 Wu et al , 211 patients
 Extended lymphadenectomy increased operating times, blood loss,
transfusion and hospital stay.
 Morbidity was increased mostly due to abdominal sepsis but mortality
did not differ.
 Extended lymphadenectomy led to significantly higher 5-year Overall
Survival but no difference in the Recurrence Rates was seen in the cases
with R0 resection.
D2 distal gastrectomy
Morbidity, mortality and perioperative outcomes in the RCTs
Overall Survival Following D1 versus D2 Lymphadenectomy
Role of Splenectomy and Pancreatectomy
 The overall consensus is that routine splenectomy and distal
pancreatectomy during D2 dissection has no long-term survival benefit
and may even be counter productive.
 However it may be performed for selected patients with
1. T3 tumors or
2. direct invasion or
3. metastasis at the splenopancreatic hilum.
Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric Adenocarcinoma. Annals of
surgery · March 2011 DOI: 10.1097
Concept of Stage Migration
 For stages I–III, stage for stage overall survival is 14–30% lower for
SEER database patients.
 At MSKCC (80% of patients receive a D2 ), stage for stage overall
survival is intermediate between SEER database patients and
NCC/SNUH patients
 Reason
1. Routine D2 lymphadenectomy, greater number of nodes are
examined.
2. Shifted nearly a third of patients from N1 to N2 disease.
Conclusion
 EGC --- D1 /D1+ surgery is only to patients not fitted for less invasive
treatment.
 AGC --- debate on the extent of nodal dissection open for many decades.
 While D2 gastrectomy - standard procedure in eastern countries, mostly based
on observational and retrospective studies,
 Japanese D2 with pancreas preservation – a safe radical treatment for gastric
cancer in selected western patients treated in experienced centers.
West meets the East
 D2 is an accepted minimal standard procedure
 D2 lymphadenectomy with spleen and pancreas preservation can be
performed safely with excellent survival outcomes.
 Significant improvement in overall survival is observed with D2
lymphadenectomy, without increased surgical morbidity and mortality.
 Minimally invasive surgery for gastric cancer including D2 Gastrectomy
is the way of the future.
THANK
YOU

More Related Content

What's hot

Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016Mohamed Abdulla
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMKanhu Charan
 
Satyajeet Carcinoma Stomach management
Satyajeet Carcinoma Stomach management Satyajeet Carcinoma Stomach management
Satyajeet Carcinoma Stomach management Satyajeet Rath
 
Retroperitoneal lymph node dissection kaushal
Retroperitoneal lymph node dissection kaushalRetroperitoneal lymph node dissection kaushal
Retroperitoneal lymph node dissection kaushalyadavkaushal
 
Management Of Liver M E T A S T A S I S Patient Selection
Management Of Liver   M E T A S T A S I S   Patient SelectionManagement Of Liver   M E T A S T A S I S   Patient Selection
Management Of Liver M E T A S T A S I S Patient SelectionSumit Roy
 
MESORECTUM TARGET DELINEATION
MESORECTUM TARGET DELINEATIONMESORECTUM TARGET DELINEATION
MESORECTUM TARGET DELINEATIONKanhu Charan
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Ashutosh Mukherji
 
Satyajeet oesophagus management
Satyajeet oesophagus managementSatyajeet oesophagus management
Satyajeet oesophagus managementSatyajeet Rath
 
Neoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaNeoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaAnkita Singh
 
Neoadjuvant Therapy ca rectum
Neoadjuvant Therapy ca rectum Neoadjuvant Therapy ca rectum
Neoadjuvant Therapy ca rectum Dr Harsh Shah
 
Role of chemotherapy in carcinoma stomach
Role of chemotherapy in carcinoma stomachRole of chemotherapy in carcinoma stomach
Role of chemotherapy in carcinoma stomachSailendra Parida
 
Total Nroadjuvant Therapy- Carcinoma Rectum
Total Nroadjuvant Therapy- Carcinoma RectumTotal Nroadjuvant Therapy- Carcinoma Rectum
Total Nroadjuvant Therapy- Carcinoma RectumRohit Kabre
 

What's hot (20)

Cross trial
Cross trialCross trial
Cross trial
 
Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016Total neoadjuvant therapy for rectal cancer 2016
Total neoadjuvant therapy for rectal cancer 2016
 
RAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUMRAPIDO TRIAL RECTUM
RAPIDO TRIAL RECTUM
 
Satyajeet Carcinoma Stomach management
Satyajeet Carcinoma Stomach management Satyajeet Carcinoma Stomach management
Satyajeet Carcinoma Stomach management
 
Retroperitoneal lymph node dissection kaushal
Retroperitoneal lymph node dissection kaushalRetroperitoneal lymph node dissection kaushal
Retroperitoneal lymph node dissection kaushal
 
Management Of Liver M E T A S T A S I S Patient Selection
Management Of Liver   M E T A S T A S I S   Patient SelectionManagement Of Liver   M E T A S T A S I S   Patient Selection
Management Of Liver M E T A S T A S I S Patient Selection
 
LANDMARK CHEMOTHERAPY AND RADIATION TRIALS IN GASTRIC CANCER.pptx
LANDMARK CHEMOTHERAPY AND RADIATION TRIALS IN GASTRIC CANCER.pptxLANDMARK CHEMOTHERAPY AND RADIATION TRIALS IN GASTRIC CANCER.pptx
LANDMARK CHEMOTHERAPY AND RADIATION TRIALS IN GASTRIC CANCER.pptx
 
MESORECTUM TARGET DELINEATION
MESORECTUM TARGET DELINEATIONMESORECTUM TARGET DELINEATION
MESORECTUM TARGET DELINEATION
 
Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017Gastric cancer contouring panel discussion, icc 2017
Gastric cancer contouring panel discussion, icc 2017
 
Peritoneal carcinomatosis
Peritoneal carcinomatosisPeritoneal carcinomatosis
Peritoneal carcinomatosis
 
Satyajeet oesophagus management
Satyajeet oesophagus managementSatyajeet oesophagus management
Satyajeet oesophagus management
 
Neoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinomaNeoadjuvant therapy in colorectal carcinoma
Neoadjuvant therapy in colorectal carcinoma
 
Neoadjuvant Therapy ca rectum
Neoadjuvant Therapy ca rectum Neoadjuvant Therapy ca rectum
Neoadjuvant Therapy ca rectum
 
Carcinoma esophagus 2020
Carcinoma esophagus 2020Carcinoma esophagus 2020
Carcinoma esophagus 2020
 
Role of chemotherapy in carcinoma stomach
Role of chemotherapy in carcinoma stomachRole of chemotherapy in carcinoma stomach
Role of chemotherapy in carcinoma stomach
 
Radiotherapy planning for vulvar cancer September 2020
Radiotherapy planning for vulvar cancer  September 2020Radiotherapy planning for vulvar cancer  September 2020
Radiotherapy planning for vulvar cancer September 2020
 
Land mark trials gastric cancer
Land mark trials gastric cancerLand mark trials gastric cancer
Land mark trials gastric cancer
 
Role of surgery in testicular cancer
Role of surgery in testicular cancerRole of surgery in testicular cancer
Role of surgery in testicular cancer
 
Cross trial
Cross trialCross trial
Cross trial
 
Total Nroadjuvant Therapy- Carcinoma Rectum
Total Nroadjuvant Therapy- Carcinoma RectumTotal Nroadjuvant Therapy- Carcinoma Rectum
Total Nroadjuvant Therapy- Carcinoma Rectum
 

Similar to D2 distal gastrectomy

D2 distal gastrectomy final
D2 distal gastrectomy finalD2 distal gastrectomy final
D2 distal gastrectomy finalDr Amit Dangi
 
D2 gastrectomy
D2 gastrectomyD2 gastrectomy
D2 gastrectomyDeep Goel
 
Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?King Hussien Cancer Center
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer managementNabeel Yahiya
 
Evidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerEvidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerPradeep Dhanasekaran
 
surgical management of gastric cancer
surgical management of gastric cancersurgical management of gastric cancer
surgical management of gastric cancerSumita Pradhan
 
Proximal Gastrectomy for Early Gastric Cancer
Proximal Gastrectomy for Early Gastric CancerProximal Gastrectomy for Early Gastric Cancer
Proximal Gastrectomy for Early Gastric Cancerjim kuok
 
3DCRT vs IMRT in ca. stomach
3DCRT vs IMRT in ca. stomach3DCRT vs IMRT in ca. stomach
3DCRT vs IMRT in ca. stomachDrAkhileshMishra
 
Gastro Esophageal Reflux Disease
Gastro Esophageal Reflux DiseaseGastro Esophageal Reflux Disease
Gastro Esophageal Reflux DiseaseApollo Hospitals
 
Radiotherapy in Extra Nodal Lymphomas
Radiotherapy in Extra Nodal LymphomasRadiotherapy in Extra Nodal Lymphomas
Radiotherapy in Extra Nodal LymphomasMohd Waseem Raza
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Siewhong Ho
 
Gastric cancer- surgical management.pptx
Gastric cancer- surgical management.pptxGastric cancer- surgical management.pptx
Gastric cancer- surgical management.pptxSomanathRayakodi1
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancersAshutosh Mukherji
 
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...Goto Pablo
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)European School of Oncology
 
Esophageal carcinoma trials
Esophageal carcinoma trialsEsophageal carcinoma trials
Esophageal carcinoma trialskoduruvijay7
 
Hypopharynxmanagement
HypopharynxmanagementHypopharynxmanagement
HypopharynxmanagementNilesh Kucha
 

Similar to D2 distal gastrectomy (20)

D2 distal gastrectomy final
D2 distal gastrectomy finalD2 distal gastrectomy final
D2 distal gastrectomy final
 
D2 gastrectomy
D2 gastrectomyD2 gastrectomy
D2 gastrectomy
 
Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?Can the laparoscopic approach to D2 gastrectomy be justified?
Can the laparoscopic approach to D2 gastrectomy be justified?
 
Gastric cancer management
Gastric cancer managementGastric cancer management
Gastric cancer management
 
Evidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric CancerEvidence based Surgical Management of Esophageal and Gastric Cancer
Evidence based Surgical Management of Esophageal and Gastric Cancer
 
surgical management of gastric cancer
surgical management of gastric cancersurgical management of gastric cancer
surgical management of gastric cancer
 
Proximal Gastrectomy for Early Gastric Cancer
Proximal Gastrectomy for Early Gastric CancerProximal Gastrectomy for Early Gastric Cancer
Proximal Gastrectomy for Early Gastric Cancer
 
3DCRT vs IMRT in ca. stomach
3DCRT vs IMRT in ca. stomach3DCRT vs IMRT in ca. stomach
3DCRT vs IMRT in ca. stomach
 
Gastro Esophageal Reflux Disease
Gastro Esophageal Reflux DiseaseGastro Esophageal Reflux Disease
Gastro Esophageal Reflux Disease
 
Radiotherapy in Extra Nodal Lymphomas
Radiotherapy in Extra Nodal LymphomasRadiotherapy in Extra Nodal Lymphomas
Radiotherapy in Extra Nodal Lymphomas
 
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
Management of renal cell carcinoma - presented at Asian Oncology Summit 2013
 
Tumors
TumorsTumors
Tumors
 
Gastric cancer- surgical management.pptx
Gastric cancer- surgical management.pptxGastric cancer- surgical management.pptx
Gastric cancer- surgical management.pptx
 
Radiotherapy for bladder cancers
Radiotherapy for bladder cancersRadiotherapy for bladder cancers
Radiotherapy for bladder cancers
 
Ca stomach
Ca stomachCa stomach
Ca stomach
 
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
Laparoscopy-assisted distal gastrectomy with D1+β compared with D1+α lymph no...
 
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
MON 2011 - Slide 20 - P. Rougier - Gastric and pancreatic cancers (part I)
 
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
MCO 2011 - Slide 22 - P. Rougier - Gastric and pancreatic cancers (part I)
 
Esophageal carcinoma trials
Esophageal carcinoma trialsEsophageal carcinoma trials
Esophageal carcinoma trials
 
Hypopharynxmanagement
HypopharynxmanagementHypopharynxmanagement
Hypopharynxmanagement
 

More from Mahesh Raj

NEO TRIAL RECTUM.pptx
NEO TRIAL RECTUM.pptxNEO TRIAL RECTUM.pptx
NEO TRIAL RECTUM.pptxMahesh Raj
 
Surgical Needles.pptx
Surgical Needles.pptxSurgical Needles.pptx
Surgical Needles.pptxMahesh Raj
 
Carcinoma Gall bladder
Carcinoma Gall bladderCarcinoma Gall bladder
Carcinoma Gall bladderMahesh Raj
 
Intestinal transplant
Intestinal transplantIntestinal transplant
Intestinal transplantMahesh Raj
 
Robotic GI surgery
Robotic GI surgeryRobotic GI surgery
Robotic GI surgeryMahesh Raj
 
Pelvic anatomy
Pelvic anatomyPelvic anatomy
Pelvic anatomyMahesh Raj
 
Indeterminate biliary stricture
Indeterminate biliary strictureIndeterminate biliary stricture
Indeterminate biliary strictureMahesh Raj
 
Peritoneal surface malignancy
Peritoneal surface malignancyPeritoneal surface malignancy
Peritoneal surface malignancyMahesh Raj
 
Thoracic outlet syndrome
Thoracic outlet syndromeThoracic outlet syndrome
Thoracic outlet syndromeMahesh Raj
 
Salivary gland tumor
Salivary gland tumorSalivary gland tumor
Salivary gland tumorMahesh Raj
 

More from Mahesh Raj (14)

NEO TRIAL RECTUM.pptx
NEO TRIAL RECTUM.pptxNEO TRIAL RECTUM.pptx
NEO TRIAL RECTUM.pptx
 
Surgical Needles.pptx
Surgical Needles.pptxSurgical Needles.pptx
Surgical Needles.pptx
 
Carcinoma Gall bladder
Carcinoma Gall bladderCarcinoma Gall bladder
Carcinoma Gall bladder
 
Cross trial
Cross trialCross trial
Cross trial
 
Intestinal transplant
Intestinal transplantIntestinal transplant
Intestinal transplant
 
Robotic GI surgery
Robotic GI surgeryRobotic GI surgery
Robotic GI surgery
 
Pelvic anatomy
Pelvic anatomyPelvic anatomy
Pelvic anatomy
 
Indeterminate biliary stricture
Indeterminate biliary strictureIndeterminate biliary stricture
Indeterminate biliary stricture
 
Peritoneal surface malignancy
Peritoneal surface malignancyPeritoneal surface malignancy
Peritoneal surface malignancy
 
Cervical rib
Cervical ribCervical rib
Cervical rib
 
Thoracic outlet syndrome
Thoracic outlet syndromeThoracic outlet syndrome
Thoracic outlet syndrome
 
Ranula
RanulaRanula
Ranula
 
Lymphoma
LymphomaLymphoma
Lymphoma
 
Salivary gland tumor
Salivary gland tumorSalivary gland tumor
Salivary gland tumor
 

Recently uploaded

EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdfHongBiThi1
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.aarjukhadka22
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)kishan singh tomar
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxMAsifAhmad
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.pptRamDBawankar1
 

Recently uploaded (20)

Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdfSGK ĐIỆN GIẬT ĐHYHN        RẤT LÀ HAY TUYỆT VỜI.pdf
SGK ĐIỆN GIẬT ĐHYHN RẤT LÀ HAY TUYỆT VỜI.pdf
 
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
Bulimia nervosa ( Eating Disorders) Mental Health Nursing.
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)High-Performance Thin-Layer Chromatography (HPTLC)
High-Performance Thin-Layer Chromatography (HPTLC)
 
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptxDNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
DNA nucleotides Blast in NCBI and Phylogeny using MEGA Xi.pptx
 
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D.  Bawankar.pptPharmacokinetic Models by Dr. Ram D.  Bawankar.ppt
Pharmacokinetic Models by Dr. Ram D. Bawankar.ppt
 

D2 distal gastrectomy

  • 1. PRESENTER: DR AJAY MODERATOR: DR SAKET KUMAR SGE KGMU, Current Evidence of D1 - D2 Gastrectomy
  • 2. OUTLINE  INTRODUCTION  NODAL STATIONS  DEFINITIONS  CURRENT EVIDENCE 1. D1 GASTRECTOMY 2. D2 GASTRECTOMY  CONCLUSION
  • 3. INTRODUCTION  Gastric cancer is the second leading worldwide cause of cancer death and the fourth most common cancer .  The high mortality rate - advanced disease at presentation and relatively aggressive biology.  Early lesions - asymptomatic and infrequently detected  Prognosis has improved, attributable to advances in surgical treatment, postoperative care, and multimodality therapy.
  • 4.  In all cases surgery is the standard of care for all resectable tumours: radical gastrectomy with regional lymphadenectomy (Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.Songun I et al Lancet Oncol. 2010 May; 11(5):439-49)  Nodal involvement - most important prognostic factor. Hence the importance to lymphadenectomy and its extension.
  • 6. TIMELINE OF EARLY TRENDS 1950s  Failure of limited surgery to control disease loco-regionally by Gordon McNeer.  >20% cancer recurrence in the non-resected perigastric nodes or the gastric bed 1960s  the Japanese Society suggested removal of the appropriate number of tiers would increase the chance of negative “lymphadenectomy margins”
  • 7. INTRODUCTION  The lymph node stations - precisely defined by the Japanese Gastric Cancer Association (JGCA), formerly known as the Japanese Research Society for Gastric Cancer  Aim of Japanese classification  a common language for the clinico- pathological description of gastric cancer.  Previously the JGCA divided these stations into four levels (N1 through N4)
  • 9. DEFINITIONS OF DIFFERENT LEVELS OF LYMPH NODE DISSECTION  For total gastrectomy 1. D1 lymphadenectomy are stations from No.1 to 7; 2. D1+ includes D1 stations plus stations No.8a, 9, and 11p, and 3. D2 includes D1 stations plus stations No.8a, 9, 10, 11p, 11d, and 12a. For tumors invading the esophagus, 1. D1+ includes N0. 110 and 2. D2 includes Nos. 19,20,110 and 111.
  • 10.  For distal gastrectomy, 1. D1 lymphadenectomy includes stations No.1, 3, 4sb, 4d, 5, 6 and 7; 2. D1+ includes D1 stations plus stations No.8a, and 9, and 3. D2 includes D1 stations plus stations No.8a, 9, 11p, and 12a.
  • 11. D1 Gastrectomy  Early forms not suitable for endoscopic treatment -> a D1 or D1 plus lymphadenectomy in cases with clinically negative nodes. (Japanese gastric cancer treatment guidelines 2010 (ver. 3) 2011 Jun; 14(2):113-23) D1 lymphadenectomy along with 1. proximal gastrectomy and 2. pylorus preserving gastrectomy only recommended for T1N0 disease.  When lymph nodes are clinically positive, a D2 dissection 1. removal of stations 12a and 11p in subtotal gastrectomy, and 2. stations 12a, 11d and 10 in total gastrectomy
  • 12. D2 Gastrectomy  Systematic (D2) Lymphadenectomy  Resection of the perigastric lymph nodes and those along the feeding vessels (N2) with the gastrectomy specimen.  will vary according to the position of the primary tumour
  • 13. D2 Gastrectomy Indication  Curative Treatment for Resectable cancer of stomach (Results are best in patients with stage II and IIIa disease) Contraindication  Stage IV disease
  • 14. D2 Lymphadenectomy – An ACCEPTED STANDARD procedure for gastric cancer Why ? CURRENT EVIDENCE
  • 15. Rationale for D2 resections  LN metastasis – a significant prognostic factor  Occult metastasis in N2 nodes of JRSGC in EGC(2-17%)  Decreased incidence of recurrence in gastric bed & perigastric lymphatics  Appropriate staging & standardisation of results  Absence of a truly effective adjuvant therapy
  • 16. Japanese and Korean experience 5yr survival rates by Pathologic stage Stage 1st period 1963-66 2ndperiod 1969-73 3rdperiod 1974-78 4th period 1979-90 I 94.4% 96.4% 96.6% 100% II 56.1% 71.8% 72% 81.2% III 30.1% 43.8% 44.8% 61% IV 9.3% 13.1% 7.7% 14% • D2 - accepted in Far East as the standard treatment for both (EGC) and (AGC) for many decades.(mostly based on observational and retrospective studies)
  • 17. 5yr survival rates by LN dissection Stage 1st period 1963-66 2ndperiod 1969-73 3rdperiod 1974-78 4th period 1979-90 D0 26% 20.5% 18.4% 32.5% D1 42.4% 46% 49.8% 62.1% D2/D3 48.1% 61.6% 64.2% 76.9% Japanese experience
  • 18. Western experience  Surgeons from the West have conventionally preferred the D1 approach because of (a) lower incidence of gastric cancer and therefore scant opportunities (b) lack of training in performing D2 resection compared with their Japanese counterpart (c) technical demands with unproven benefits based on a number of RCTs (d) fear of increased risk of complications and even deaths
  • 19. Initial Western experience Results of prospective randomized trials Name Study period No of pts Post op morbid Post opMort 5yr survival South Africa (Dent et al) 1982- 1986 D1 D2 D1 D2 D1 D2 D1 D2 22 21 15 30 0 0 0.69 0.67 Dutch Gastric cancer trial 1983- 1993 380 331 25 43 4 10 42 47 MRC trial,UK 1986- 1993 200 200 28 46 6.5 13 35 33 •MRC, Dutch and Italian RCTs - conducted to show a survival benefit of D2 over D1. •Both the MRC and the Dutch trials failed to show a survival benefit
  • 20.  Only 15 years after the conclusion of accrual, Dutch trial reported significant decrease of recurrence after D2 procedure.  Italian RCT could demonstrate a benefit for patients treated with D2 gastrectomy without splenopancreatectomy.  It has been suggested in several national guidelines including NCCN as the recommended procedure for patients with AGC.
  • 22. South African Trial  Dent et al in South Africa randomized 43patients.  Major findings were that blood transfusion requirements, operating time and hospital stay were longer with extended lymphadenectomy.  At a median follow-up of 3.1 years no benefit regarding survival was seen.
  • 23. Hong Kong Trial  Robetson et al randomized 55 patients in Hong Kong  Operating time, transfusion requirements and hospital stay, all increased with extended lymphadenectomy.  Contrary to the expectations overall survival was significantly worse and this was attributed to the impact of increased blood transfusion.
  • 24. UK MRC Trial  In hospital mortality was high in both groups compared to high volume Asian centers, and significantly higher in the D2 versus D1 arm (13 vs. 6.5%)  No significant difference in overall survival at 5 years (D1 35%; D2 33%; P = 0.43).  Cons The authors found - additional mortality in the D2 group could be attributed to the performance of distal pancreatectomy and splenectomy
  • 25. Dutch Trial  Patients in the D2 group had 1. significantly higher rates of complications (43 vs. 25%; P < 0.001) 2. post-operative death (10 vs. 4% P = 0.004).  Overall survival at 5 years was not statistically different (45% for D1; 47% for D2).
  • 26.  15 year-follow up of the Dutch study [Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Songun et al Lancet Oncol. 2010 May; 11(5):439-49] 1. Loco-regional recurrence rate is significantly lower in patients treated with D2 lymphadenectomy vs D1. 2. Survival benefit with the enlarged dissection.
  • 27.  Studies recently demonstrated that even in Europe trained surgeons could safely perform D2 with spleen and pancreas preservation and  More favourable recurrence pattern and cancer-related survival,  D2 seemed to be the recommended treatment for patients with resectable gastric cancer . [Extended lymph node dissection without routine spleno-pancreatectomy for treatment of gastric cancer: low morbidity and mortality rates in a single center series of 250 patients.Biffi R et al J Surg Oncol. 2006 Apr 1; 93(5):394-400]
  • 28.  Limitations -- outcome of multivariate analysis was not reported -- protocol deviations 1. noncompliance (ie, performance of less dissection than specified) 2. contamination (ie, performance of more extensive dissection than specified)
  • 29. Italian Trial  Italian Research Group for Gastric Cancer (GIRCG) database 1. Proximal tumors and diffuse-mixed type show a relative increase 2. Endoscopic resections, are much less adopted in the West. 3. The GIRCG guidelines advice a D2 lymphadenectomy in clinically early forms not suitable for endoscopic treatment (The SIC-GIRCG 2013 Consensus Conference on Gastric Cancer.De Manzoni G et al Updates Surg. 2014 Mar; 66(1):1-6.)
  • 30.  D2 dissection - limited risk of complications and mortality in the West, when performed in specialized centers and avoiding spleno-pancreatectomy [RCT comparing survival after D1 or D2 gastrectomy for gastric cancer.Degiuli M et al Italian Gastric Cancer Study Group. Br J Surg. 2014 Jan; 101(2):23-31].  Only in selected cases more limited procedures (D1 plus) are adviced by the GIRCG group. 1. high-risk patients (age > 70 yrs) 2. early forms with favourable pathological characteristics.
  • 31.  Limitations 1. Poor accrual 2. Closed after 8 years with a low statistical power as only 267 patients were randomized.
  • 32. Taiwanese Trial  Wu et al , 211 patients  Extended lymphadenectomy increased operating times, blood loss, transfusion and hospital stay.  Morbidity was increased mostly due to abdominal sepsis but mortality did not differ.  Extended lymphadenectomy led to significantly higher 5-year Overall Survival but no difference in the Recurrence Rates was seen in the cases with R0 resection.
  • 34. Morbidity, mortality and perioperative outcomes in the RCTs
  • 35. Overall Survival Following D1 versus D2 Lymphadenectomy
  • 36. Role of Splenectomy and Pancreatectomy  The overall consensus is that routine splenectomy and distal pancreatectomy during D2 dissection has no long-term survival benefit and may even be counter productive.  However it may be performed for selected patients with 1. T3 tumors or 2. direct invasion or 3. metastasis at the splenopancreatic hilum. Meta-Analysis of D1 Versus D2 Gastrectomy for Gastric Adenocarcinoma. Annals of surgery · March 2011 DOI: 10.1097
  • 37. Concept of Stage Migration  For stages I–III, stage for stage overall survival is 14–30% lower for SEER database patients.  At MSKCC (80% of patients receive a D2 ), stage for stage overall survival is intermediate between SEER database patients and NCC/SNUH patients  Reason 1. Routine D2 lymphadenectomy, greater number of nodes are examined. 2. Shifted nearly a third of patients from N1 to N2 disease.
  • 38. Conclusion  EGC --- D1 /D1+ surgery is only to patients not fitted for less invasive treatment.  AGC --- debate on the extent of nodal dissection open for many decades.  While D2 gastrectomy - standard procedure in eastern countries, mostly based on observational and retrospective studies,  Japanese D2 with pancreas preservation – a safe radical treatment for gastric cancer in selected western patients treated in experienced centers. West meets the East
  • 39.  D2 is an accepted minimal standard procedure  D2 lymphadenectomy with spleen and pancreas preservation can be performed safely with excellent survival outcomes.  Significant improvement in overall survival is observed with D2 lymphadenectomy, without increased surgical morbidity and mortality.  Minimally invasive surgery for gastric cancer including D2 Gastrectomy is the way of the future.